Auxly Cannabis Group Inc. · TSX:XLY
Auxly Cannabis — Investor Presentation (July 2018)
34 slides from Auxly Cannabis's investor presentation, July 2018

Slide 1: Corporate Presentation
Corporate Presentation July 2018 Auxly Cannabis Group Inc www.auxly.com

Slide 2: Legal Disclaimer
Legal Disclaimer Forward-looking Information differ materially from those expressed or implied by the forward-looking information, general The information provided herein is not intended to provide financial, tax, legal or accounting This corporate document contains “forward-looking statements” and

Slide 3: Our Vision From the Outset
OUR VISION FROM THE OUTSET: To become the first and foremost streaming enterprise in the cannabis industry. As our business platform began to take shape, new opportunities forged new relationships, and those relationships are now the foundation atop which our company is built. Today, our vision rema

Slide 4

Slide 5: A Team Dedicated to Growth
A TEAM DEDICATED TO GROWTH: Auxly’s leadership comprises industry first-movers, enterprising visionaries, and deep-experience specialists undeniably dedicated to creating value for our partners and the industry as a whole. Our diversified experience and proven track record ensures partners have acce

Slide 6: State of the Nation
State of the Nation

Slide 7: Medical and Non-Medical Market
Medical Market Health Canada introduced the basic medical cannabis program Patient registrations have continued to climb with over 200,000 patients registered Health Canada conservatively estimates that the size of the medical cannabis ealthy growing H in 2001. with LPs nation wide and a 5% month-ov

Slide 8: Cannabis Industry Overview
CANNABIS INDUSTRY OVERVIEW: The legalization of an existing market is predicted to reap large benefits. Market Research $20.0 16.0 Based on Market Surveys and includes the current CIBC World Markets believes that the cannabis market will reach Black Market $6.8 billion by 2020, outpacing the spirits

Slide 9: Cannabis Industry Timeline
CANNABIS INDUSTRY TIMELINE APRIL 2017 DECEMBER 2017 SUMMER 2019 2021+ Cannabis Act Ontario becomes first Sales of Normalized state tabled in the House province to pass its edibles. of the recreational of Commons. cannabis legislation. market. NOVEMBER 2017 Q3 2018 2019/2020 Cannabis Act Legalization

Slide 10: Cannabis Industry Growth
CANNABIS INDUSTRY GROWTH: Projected Stabilized Values By 2024 ($ Billions In Revenue). Medical: $1.3B Recreational: $8.7B Ancillary: $22.6B International: $30B Health Canada projects the current medical The Canadian recreational cannabis market is The combined value of the recreational and ancil- Wi

Slide 11: Domestic Demand Expected to Outstrip Supply Until 2021
DOMESTIC DEMAND EXPECTED TO OUSTRIP SUPPLY UNTIL 2021: Projected supply and demand by 2021. Assumes all LPs’ capacity expansions are completed on KG schedule and as planned 1,200 1,000 800 600 400 200 0 2015 A 2016 A 2017 A 2018 E 2019 E 2020 E 2021 E SUPPLY SUPPLY TOTAL DRIED FLOWER DEMAND Internat

Slide 12: Industry Funded Capacity
INDUSTRY FUNDED CAPACITY 300,000 Based on our estimates, there is currently ~1.5mm kg/yr of announced capacity expected by 2020 Targeted 2020 Current 250,000 200,000 150,000 100,000 50,000 0 ACB WEED APH LEAF XLY THCX EMH OGI MARI Tilray WMD FIRE TRST MJN HVT HIP ABCN NINE TGOD EMC Auxly Cannabis Gr

Slide 13: Platform for Growth
Platform for Growth

Slide 14: Model for Growth
MODEL FOR GROWTH: This is simple to articulate — as it should be. Auxly is creating a world-class platform by forming partnerships with best-in-class cultivators, product innovators and developers, researchers and marketers. We provide our partners with ongoing cornerstone support in cultivation, re

Slide 15: Industry Is Not Without Risks
INDUSTRY IS NOT WITHOUT RISKS: The Auxly team have observed common themes that have prevented producers from reaching their full potential. Licensing Risk Scaling Problems Construction Risk While the number of LPs continue to climb, sales Cannabis is a difficult plant to grow at scale while Building

Slide 16: How We Identify Risks
HOW WE IDENTIFY RISKS: Auxly’s team executes a specialized diligence process to select, structure and monitor its streaming partner agreements. We go deep on all aspects of risk before deploying investor capital. 1 2 3 4 5 6 Corporate Review Regulatory Financial Projections Infrastructure and Cultiv

Slide 17: How We Mitigate Risks and Add Value
HOW WE MITIGATE RISKS AND ADD VALUE: The Auxly platform is about more than just deploying capital, we are diversifying our streaming deals and have devel- oped the ancillary tools and infrastructure to make those streams successful. Infrastructure Regulatory Expertise Access to Genetics Innovative F

Slide 18: How We View Our Business
HOW WE VIEW OUR BUSINESS UPSTREAM MIDSTREAM DOWNSTREAM Streaming Partners Dosecann: Value Add and IP Distribution and Sales 13 Partners Extraction, Processing, Brands/Licensing, Medical Market, Provincial Retail, Pharmacies, R&D, Manufacturing Convenience Stores, International Domestic International

Slide 19: Upstream Supply: Auxly Partner Ramp-Up
UPSTREAM SUPPLY: Auxly Partner Ramp-Up 2018 2019 2020 2021 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Kolab Project Beleave CannTX Sundial Green Relief Restoration Lands FV Pharma Lotus Robinson’s Group IDP Plan C ABcann Peter Quiring JV SGSC Inverell Pontiac Group Curative Quarterly Production

Slide 20: Midstream: Mitigating Long-Term Margin Compression
MIDSTREAM–MITIGATING LONG-TERM MARGIN COMPRESSION: Our long-term view is that margin compression for flower is inevitable and aim to capture high-mar- gin segments of the market through extracted products, infused functional foods and Natural Health Products. Dosecann Product Focus 50 40 Selling Pri

Slide 21: Downstream: Current Distribution Channels
DOWNSTREAM: Current Distribution Channels Medical Other Provincial Retailers Kolab Project: Auxly has a wholly owned Inner Spirit: Strategic alliance to supply up to licensed facility in Carleton Place, Ontario. 50% of their annual inventory requirements across their potential 95 franchise locations

Slide 22: Capitalization Table
CAPITILIZATION TABLE SHARE STRUCTURE, AS OF MAY 31, 2018 AMOUNT PERCENTAGE Common Shares Oustanding 560.9m 74.6% Stock Options 26.6m 3.4% Warrants 101.5m 13.5% Convertible Debentures (Strike at $1.55) 63.9m 8.5% Fully Diluted Shares 751.9m 100% CAPITAL STRUCTURE AMOUNT Cash Balance (as of June 30, 2

Slide 23: Appendix
Appendix

Slide 24: Appendix A: Upstream Partners - Inverell S.A.
APPENDIX A: Upstream Partners Inverell S.A. Company Overview Founder and CEO: Dr. Raúl Urbina Partner Summary Inverell is a federally licensed “Cannabis Operator” Founder and CEO of Stevia One, the lowest cost Location: Uruguay based in Montevideo, Uruguay for the large-scale out- producer of stevia

Slide 25: Appendix A: Upstream Partners - Kolab Project Inc.
APPENDIX A: Upstream Partners Kolab Project Inc. Company Overview Partner Summary The Kolab Project is a wholly owned subsidiary of Location: Ontario Auxly and a cultivation licensed producer pursuant to Facility Type: Indoor the ACMPR located near Ottawa, Ontario. Upon re- ceiving necessary approva

Slide 26: Appendix A: Upstream Partners - Robinson's Cannabis Inc.
APPENDIX A: Upstream Partners Robinson’s Cannabis Inc. Company Overview Partner Summary Robinson’s Cannabis is a wholly owned subsidiary of Location: Nova Scotia the Auxly Cannabis Group and a late-stage licensed Facility Type: Indoor producer applicant pursuant to the ACMPR located in Kentville, No

Slide 27: Appendix A: Upstream Partners - FV Pharma
APPENDIX A: Upstream Partners FV Pharma Company Overview Milestones Partner Summary FV Pharma is a large scale indoor cultivation facility Construction of initial 200,000 sq. ft. expected Location: Ontario being constructed with joint venture partner FV to be completed by December 2018 Facility Type

Slide 28: Appendix A: Upstream Partners - GreenhouseCo Joint Venture
APPENDIX A: Upstream Partners GreenhouseCo Joint Venture Company Overview Partner Summary Founder and CEO: Peter Quiring GreenhouseCo is a joint venture with world renown Location: Ontario cultivation expert Peter Quiring via a newly formed Owner and operator of South Essex Fabricating, Facility Typ

Slide 29: Appendix A: Upstream Partners - Dosecann
APPENDIX A: Upstream Partners Dosecann Company Overview Key Facts and Figures Partner Summary Dosecann is a wholly owned subsidiary of the Auxly Strategically located within PEI to take advantage Location: Prince Edward Island Cannabis Group and a licensed Dealer applicant pur- of existing robust bi

Slide 30: Appendix B: Case Study: Legalized Recreational Use in the United States
APPENDIX B: Midstream Partners Case Study: Legalized Recreational Use in the United States Commentary Colorado: Category Share by Quarter Value-add product formats (derived from cannabis 100% extracts) have experienced notable growth and are 4% 4% 3% 3% 4% 4% 5% capturing a greater share of industry

Slide 31: Appendix B: Competitive Landscape
APPENDIX B: Midstream Partners Competitive Landscape Health and Vertical Description Pharma Wellness Adult Use Integration A clinical-stage biotechnology company located in Stamford, CT Cara Market Cap of USD $509 million UK based company that specializes in plant-derived cannabinoid therapeutics GW

Slide 32: Appendix C: Team
APPENDIX C: Team Ian Rapsey Brad McNamee Diego Gianelli Travis Wong Chief Creative Officer Chief Infrastructure Officer SVP, Global Chief Marketing and Sales Officer Vice President, Finance Ian is an award-winning creative director that has worked Brad is a second-generation mechanical contractor sp

Slide 33: Appendix C: Team
APPENDIX C: Team Sarah Bain Greg Boone Tina Woollard Peter Crooks Vice President, External Affairs CEO, Dosecann Chief Science Officer, Dosecann Chief of Product Innovation, Dosecann Sarah is an expert communications strategist with more Greg is a seasoned entrepreneur who has over 20 years of Tina

Slide 34: Auxly
Auxly
Source: Internet Archive copy of auxly.com
More decks from Auxly Cannabis Group Inc.
Investor Presentation (November 2026)27 slides · November 2026
Investor Presentation (August 2026)27 slides · August 2026
Q1 2026 Earnings Presentation26 slides · May 14, 2026
Q4 2025 Earnings Presentation27 slides · Mar 27, 2026
Investor Presentation (November 2025)24 slides · November 2025
Q2 2025 Earnings Presentation22 slides · August 2025